Experience with the use of immunobiological drugs in the treatment of patients with severe bronchial asthma and comorbidities

Introduction . The accumulation of clinical experience in the use biological therapy patients with severe bronchial asthma (SBA) real-world practice possible identification additional, previously undescribed results is practical interest. Aim goal study to present observational that reflects using benralizumab SBA city Saint Petersburg. Materials and methods We presents more than 1 year observation 18 eosinophilic (12 females, 6 males, age from 28 74, average 55 ± 11.9 years). Patients received addition standard medical management. Conducted clinical, laboratory, functional examination patients, assessment frequency exacerbations additional effects. Results It was shown inclusion complex led a significant improvement disease control, improved conduction, decrease blood eosinophilia reduction number exacerbations. Clinical examples are given evidence stabilizing effect this on course recurrent nasal polyposis positive effects granulomatous polyangiitis, manifested by SBA. Conclusions In real practice, possibility control has been confirmed. At same time, data have obtained will allow expanding indications for future.